Autologous or allogeneic transplantation in B- and T-cell lymphomas

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 1, 2012, Pages 61-73

  Schmitz, N ^a   Nickelsen, M ^a   Glass B ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

B and T cell lymphomas treatment

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE; VINDESINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOCOMPETENT CELL; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONMYELOABLATIVE CONDITIONING; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; T CELL DEPLETION; T CELL LYMPHOMA; TUMOR CELL;

EID: 84858301151     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.01.007     Document Type: Review

References (95)

1. B. Coiffier, E. Lepage, and J. Briere CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 4 2002 235 242 (Pubitemid 34438862)
2. M. Pfreundschuh, L. Trumper, and A. Osterborg CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 5 2006 379 391
3. N. Schmitz, M. Nickelsen, and M. Ziepert Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) J Clin Oncol 29 15 suppl 2011 8002
4. M. Pfreundschuh, J. Schubert, and M. Ziepert Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2 2008 105 116
5. W. Hiddemann, M. Kneba, and M. Dreyling Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 106 12 2005 3725 3732 (Pubitemid 41742196)
6. R. Marcus, K. Imrie, and A. Belch CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood 105 4 2005 1417 1423 (Pubitemid 40223656)
7. G. Salles, N. Mounier, and S. De Guibert Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Blood 112 13 2008 4824 4831
8. M. Herold, A. Haas, and S. Srock Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study J Clin Oncol 25 15 2007 1986 1992 (Pubitemid 46972781)
9. S.H. Swerdlow, E. Campo, and N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 2008 International Agency for Research on Cancer (IARC) Lyon
10. N. Schmitz, L. Trumper, and M. Ziepert Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group Blood 116 18 2010 3418 3425
11. M.R. Mansour, A. Dogan, and E.C. Morris Allogeneic transplantation for hepatosplenic αβ T-cell lymphoma Bone Marrow Transplant 35 9 2005 931 934 (Pubitemid 40667639)
12. C. Haioun, E. Lepage, and C. Gisselbrecht Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 12 12 1994 2543 2551 (Pubitemid 24379637)
13. C. Haioun, E. Lepage, and C. Gisselbrecht Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte Study J Clin Oncol 18 16 2000 3025 3030 (Pubitemid 30644128)
14. A.M. Gianni, M. Bregni, and S. Siena High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma N Engl J Med 336 18 1997 1290 1298
15. G. Santini, L. Salvagno, and P. Leoni VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group J Clin Oncol 16 8 1998 2796 2802 (Pubitemid 28363045)
16. H.C. Kluin-Nelemans, V. Zagonel, and A. Anastasopoulou Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study J Natl Cancer Inst 93 1 2001 22 30 (Pubitemid 32060886)
17. U. Kaiser, I. Uebelacker, and U. Abel Randomized study to Evaluate the use of high-dose therapy as part of primary treatment for "Aggressive" lymphoma J Clin Oncol 20 22 2002 4413 4419 (Pubitemid 35334751)
18. M. Martelli, F. Gherlinzoni, and A. De Renzo Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial J Clin Oncol 21 7 2003 1255 1262 (Pubitemid 46606401)
19. N. Milpied, E. Deconinck, and F. Gaillard Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Engl J Med 350 13 2004 1287 1295 (Pubitemid 38375363)
20. A. Olivieri, G. Santini, and C. Patti Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG Ann Oncol 16 12 2005 1941 1948 (Pubitemid 41724284)
21. D.C. Betticher, G. Martinelli, and J.A. Radford Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) Ann Oncol 17 10 2006 1546 1552 (Pubitemid 44542042)
22. J. Strehl, U. Mey, and A. Glasmacher High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis Haematologica 88 11 2003 1304 1315 (Pubitemid 37456386)
23. A. Greb, J. Bohlius, and D. Schiefer High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults Cochrane Database Syst Rev 2008
24. P.J. Stiff, J.M. Unger, and J. Cook Randomized phase III.U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP {+/-} R for eight cycles to CHOP {+/-} R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL) J Clin Oncol 29 15 suppl 2011 8001
25. U. Vitolo, A. Chiappella, and E. Brusamolino A randomized multicentre phase III study for first-line treatment of young patients with high risk (aaIPI 2-3) diffuse large B-cell lymphoma (DLBCL): rituximab (R) plus dose-dense chemotherapy CHOP14/MegaCHOP14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL) Ann Oncol 22 Suppl 4 2011 072
26. S. Le Gouill, N.J. Milpied, and T. Lamy First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial J Clin Oncol 29 15 suppl 2011 8003
27. B. Glass, M. Kloess, and M. Bentz Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma Blood 107 8 2006 3058 3064
28. M. Pfreundschuh, G. Held, and S. Zeynalova Improved outcome of elderly poor-prognosis DLBCL patients with 6 × CHOP-14 and 8 Applications of rituximab (R) given over an Extended period: results of the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL) Blood 118 21 2011 592
29. T. Philip, C. Guglielmi, and A. Hagenbeek Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 333 23 1995 1540 1545
30. C. Guglielmi, F. Gomez, and T. Philip Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial J Clin Oncol 16 10 1998 3264 3269 (Pubitemid 28481620)
31. J.Y. Blay, F. Gomez, and C. Sebban The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial Blood 92 10 1998 3562 3568 (Pubitemid 28525180)
32. T. Kewalramani, A.D. Zelenetz, and S.D. Nimer Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 103 10 2004 3684 3688 (Pubitemid 38596282)
33. C. Gisselbrecht, B. Glass, and N. Mounier Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 28 27 2010 4184 4190
34. C. Gisselbrecht, B. Glass, and M. Fournier Salvage regimen with autologous stem cell transplantation with or without rituximab maintenance for relapsed diffuse large B-cell lymphoma (DLBCL): CORAL final report Ann Oncol 22 Suppl 4 2011 075
35. A. Martin, E. Conde, and M. Arnan R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 93 12 2008 1829 1836
36. A.J. Peniket, M.C. Ruiz de Elvira, and G. Taghipour An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant 31 8 2003 667 678 (Pubitemid 36553477)
37. R. Chopra, A.H. Goldstone, and R. Pearce Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data J Clin Oncol 10 11 1992 1690 1695 (Pubitemid 23059945)
38. V. Ratanatharathorn, J. Uberti, and C. Karanes Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 84 1994 1050 1055 (Pubitemid 24245868)
39. R. Storb, C. Yu, and J.L. Wagner Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 8 1997 3048 3054 (Pubitemid 27172593)
40. R. Chakraverty, G. Orti, and M. Roughton Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution Blood 116 16 2010 3080 3088
41. K.J. Thomson, E.C. Morris, and A. Bloor Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma J Clin Oncol 27 3 2009 426 432
42. A.R. Rezvani, L. Norasetthada, and T. Gooley Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience Br J Haematol 143 3 2008 395 403
43. A. Sirvent, N. Dhedin, and M. Michallet Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire Biol Blood Marrow Transplant 16 1 2010 78 85
44. R.J.W. van Kampen, C. Canals, and H.C. Schouten Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry J Clin Oncol 29 10 2011 1342 1348
45. H.E. Kohrt, B.B. Turnbull, and K. Heydari TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors Blood 114 5 2009 1099 1109
46. B. Glass, M. Nickelsen, and P. Dreger Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect Bone Marrow Transplant 34 5 2004 391 397 (Pubitemid 39232367)
47. K.S. Peggs, K. Thomson, and D.P. Hart Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses Blood 103 4 2004 1548 1556 (Pubitemid 38168677)
48. G. Lenz, M. Dreyling, and E. Schiegnitz Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group Blood 104 9 2004 2667 2674 (Pubitemid 39434946)
49. E. Deconinck, C. Foussard, and N. Milpied High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS Blood 105 10 2005 3817 3823 (Pubitemid 40656123)
50. C. Sebban, N. Mounier, and N. Brousse Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood 108 8 2006 2540 2544
51. G. Salles, J.F. Seymour, and F. Offner Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial The Lancet 377 9759 2011 42 51
52. L.H. Sehn, D. MacDonald, and S. Rubin Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 29 25 2011 3396 3401
53. F. Samaniego, F. Hagemeister, and P. McLaughlin High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria J Clin Oncol 29 15 suppl 2011 8030
54. G. Salles Is there a role for Bortezomib combinations in the management of patients with follicular lymphoma? J Clin Oncol 29 25 2011 3349 3350
55. H.C. Schouten, W. Qian, and S. Kvaloy High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol 21 21 2003 3918 3927 (Pubitemid 46606204)
56. R. Forstpointner, M. Dreyling, and R. Repp The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 104 10 2004 3064 3071 (Pubitemid 39517009)
57. C. Sebban, P. Brice, and R. Delarue Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study J Clin Oncol 26 21 2008 3614 3620
58. R. Pettengell, N. Schmitz, and C. Gisselbrecht Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy J Clin Oncol 28 15 suppl 2010 8005
59. 131 I]Tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥ 60 Years old with relapsed or refractory B-cell lymphoma J Clin Oncol 25 11 2007 1396 1402 (Pubitemid 46706888)
60. C. Gisselbrecht, D. Decaudin, and N. Mounier 90Yttrium Ibritumomab Tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma. GELA Phase II Study Blood 110 11 2007 22
61. A. Krishnan, A. Nademanee, and H.C. Fung Phase II trial of a transplantation regimen of Yttrium-90 Ibritumomab Tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma J Clin Oncol 26 1 2008 90 95
62. P. Hari, J. Carreras, and M.J. Zhang Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning Biol Blood Marrow Transplant 14 2 2008 236 245
63. S.P. Robinson, A.H. Goldstone, and S. Mackinnon Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 13 2002 4310 4316 (Pubitemid 35429668)
64. K.J. Thomson, E.C. Morris, and D. Milligan T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma J Clin Oncol 28 23 2010 3695 3700
65. S. Vigouroux, M. Michallet, and R. Porcher Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) Haematologica 92 5 2007 627 634 (Pubitemid 350147794)
66. I.F. Khouri, P. McLaughlin, and R.M. Saliba Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood 111 12 2008 5530 5536
67. J. Pinana, R. Martino, and J. Gayoso Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials Haematologica 95 7 2010 1176 1182
68. V. Fernández, O. Salamero, and B. Espinet Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma Cancer Res 70 4 2010 1408 1418
69. E. Hoster, M. Unterhalt, and B. Wormann The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial Blood 112 11 2008 3049
70. O. Hermine, E. Hoster, and J. Walewski Alternating courses of 3 × CHOP and 3 × DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European mantle Cell Lymphoma Network (MCL net) Blood 116 21 2010 110
71. W.A. Bethge, T. Lange, and C. Meisner Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study Blood 116 10 2010 1795 1802
72. C. Pott, E. Hoster, and M.H. Delfau-Larue Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study Blood 115 16 2010 3215 3223
73. N.S. Andersen, L.B. Pedersen, and A. Laurell Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma J Clin Oncol 27 26 2009 4365 4370
74. L.E. Budde, K.A. Guthrie, and B.G. Till Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation J Clin Oncol 29 22 2011 3023 3029
75. C.S. Tam, R. Bassett, and C. Ledesma Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood 113 18 2009 4144 4152
76. E. Vandenberghe, C. Ruiz de Elvira, and F.R. Loberiza Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries Br J Haematol 120 5 2003 793 800 (Pubitemid 36315101)
77. G. Cook, G.M. Smith, and K. Kirkland Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a Study of the British Society for Blood and Marrow Transplantation Biol Blood Marrow Transplant 16 10 2010 1419 1427
78. I.F. Khouri, M.S. Lee, and R.M. Saliba Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma J Clin Oncol 21 23 2003 4407 4412 (Pubitemid 46621818)
79. S.P. Robinson, A. Sureda, and C. Canals Sr. Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. An analysis from the lymphoma working party of the EBMT Blood 112 11 2008 457
80. O.A. O'Connor, B. Pro, and L. Pinter-Brown Pralatrexate in patients with relapsed or refractory peripheral T-Cell lymphoma: results from the Pivotal PROPEL study J Clin Oncol 29 9 2011 1182 1189
81. R.L. Piekarz, R. Frye, and H.M. Prince Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma Blood 117 22 2011 5827 5834
82. P. Corradini, C. Tarella, and F. Zallio Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation Leukemia 20 9 2006 1533 1538 (Pubitemid 44264095)
83. P. Reimer, T. Rudiger, and E. Geissinger Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study J Clin Oncol 27 1 2009 106 113
84. F. d'Amore, T. Relander, and G.F. Lauritzsen High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma - final analysis of a large prospective multicenter study (NLG-T-01) Blood 118 21 2011 331
85. J. Rodriguez, E. Conde, and A. Gutierrez The adjusted international prognostic index and +-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma Haematologica 92 8 2007 1067 1074 (Pubitemid 350144213)
86. S. Mercadal, J. Briones, and B. Xicoy Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann Oncol 19 5 2008 958 963 (Pubitemid 351627314)
87. C. Kyriakou, C. Canals, and A. Goldstone High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-lymphoma working party of the European group for blood and marrow transplantation J Clin Oncol 26 2 2008 218 224
88. M. Nickelsen, C. Canals Sr., and N. Schmitz Patients with mature T-cell lymphoma show high relapse rates after high dose therapy and autologous stem cell transplantation Blood 112 11 2008 774
89. M.A. Fanale, A. Forero-Torres, and J.D. Rosenblatt A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies Clin Cancer Res 18 1 2012 248 255
90. J. Schetelig, S. Fetscher, and A. Reichle Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation Haematologica 88 11 2003 1272 1278 (Pubitemid 37456382)
91. P. Corradini, A. Dodero, and F. Zallio Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells J Clin Oncol 22 11 2004 2172 2176 (Pubitemid 41095152)
92. C. Kyriakou, C. Canals, and J. Finke Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation J Clin Oncol 27 24 2009 3951 3958
93. S. Le Gouill, N. Milpied, and A. Buzyn Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire J Clin Oncol 26 14 2008 2264 2271
94. R.F. Duarte, C. Canals, and F. Onida Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 28 29 2010 4492 4499
95. B. Glass, J. Hasenkamp, and W. Jung Allogeneic stem cell transplantation for patients with relapsed or chemorefractory T-cell lymphoma: role of high intensity conditioning Ann Oncol 22 Suppl 4 2011 040